Textbook of clinical trials: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
===[[Textbook of clinical trials|Back to top]]=== | ===[[Textbook of clinical trials|Back to top]]=== | ||
'''Ethical Issues''' | === '''Ethical Issues''' === | ||
'''Helsinki agreement]]''' | |||
[[Informed consent]] | |||
[[Institutional Review Board|Investigational Review Board]] ([[IRB]]) | |||
HIPAA reidentification of patients and patient privacy | |||
Line 17: | Line 17: | ||
=== '''Regulatory issues and pathways in clinical trials''' === | === '''Regulatory issues and pathways in clinical trials''' === | ||
[[Form 1572|The 1572 form and investigator responsibilities]] | |||
[[Investigational new drug application|Investigational new drug (IND) application]] | |||
[[Investigational new drug or device exemption]] | |||
[[510K Pathway|510K pathway]] | |||
=== '''Designing Clinical Trials''' === | === '''Designing Clinical Trials''' === | ||
[[Randomized controlled trials]] versus [[observational studies]] | |||
[[Phase I trial|Phase 1 trials]] | |||
[[Pharmacokinetic]] (PK) and pharmcodynamic (PD) assessment | [[Pharmacokinetic]] (PK) and pharmcodynamic (PD) assessment | ||
[[Phase II clinical trial|Phase 2 trials]] | |||
Advancing from phase 2 to a phase 3 trial | Advancing from phase 2 to a phase 3 trial | ||
[[Phase III trials|Phase 3 trials]] | |||
[[Parallel study|Parallel]] versus dose escalation studies | [[Parallel study|Parallel]] versus dose escalation studies | ||
[[Hypothesis|Hypothesis generation]] | |||
[[Inclusion criteria|Inclusion]] and [[exclusion criteria]] | |||
[[Stratification]] | |||
[[Primary end point|Primary endpoint]] | |||
Secondary endpoints and [[Exploratory research|exploratory endpoints]] | |||
[[Surrogate endpoint|Surrogate endpoints]] | |||
[[Sample size]] and [[Statistical power|power calculations]] | |||
[[Protocols|Protocol creation]] | |||
[[Abbreviations used in clinical trials]] | [[Abbreviations used in clinical trials]] | ||
Line 61: | Line 64: | ||
=== '''Operationalizing Clinical Trials''' === | === '''Operationalizing Clinical Trials''' === | ||
Principal investigator role | |||
Executive committee role | |||
Steering committee role | |||
Nurse coordinator clinical research associate role | |||
Monitor role | |||
Sponsor role | |||
Randomization service | |||
Central laboratory facility | |||
EKG core laboratory | |||
Angiographic core laboratory | |||
MRI core laboratory | |||
Genetics core laboratory | |||
Biomarker core laboratory | |||
Identification of sites | |||
[[Randomization]] | |||
[[Blinding]] | |||
[[Recruitment status|Recruitment of study participants]] | |||
[[Electronic data capture|Electronic data collection]] | |||
Schedule of events | |||
Concomitant medications | |||
Clinical event committee or event adjudication committee | |||
Adverse events, serious adverse events and serious unexpected events | |||
Data safety monitoring board (DSMB) | |||
Study drug discontinuation, withdrawal of consent, incomplete follow up and lost to follow up patients | |||
Protocol adherence | |||
Storage and handling of investigational product | |||
Data management and designing an electronic data capture form | |||
Source documents | |||
Study completion and close out | |||
Protocol amendments | |||
Publication committee | |||
=== '''Statistical Analysis of Clinical Trials''' === | === '''Statistical Analysis of Clinical Trials''' === | ||
Cleaning a dataset | |||
Summary statistics | |||
[[Intention to treat analysis|Intent to treat]] versus [[Modified intention to treat analysis|modified intent to treat]] versus as treated | |||
[[Student's t-test|Student's t tests]] and [[analysis of variance]] | |||
[[Chi-square test|Chi square analysis]] and [[Fisher's exact test]] | |||
[[Logistic regression]] | |||
[[Multivariate analysis|Multivariate modeling]] | |||
[[Survival analysis]] | |||
Handling [[missing data]] | |||
Subgroup and [[Interaction (statistics)|interaction analyses]] | |||
Net clinical benefit analyses | |||
Cost effectiveness analyses | |||
Quality adjusted life year analyses | |||
Interim analyses and [[Futility in clinical research|futility analyses]] | |||
Reporting results and how to write a manuscript | |||
[[Meta-analysis]] | |||
Positive publication bias | |||
Revision as of 13:39, 25 October 2019
Back to top
Ethical Issues
Helsinki agreement]]
Investigational Review Board (IRB)
HIPAA reidentification of patients and patient privacy
Regulatory issues and pathways in clinical trials
The 1572 form and investigator responsibilities
Investigational new drug (IND) application
Investigational new drug or device exemption
Designing Clinical Trials
Randomized controlled trials versus observational studies
Pharmacokinetic (PK) and pharmcodynamic (PD) assessment
Advancing from phase 2 to a phase 3 trial
Parallel versus dose escalation studies
Inclusion and exclusion criteria
Secondary endpoints and exploratory endpoints
Sample size and power calculations
Abbreviations used in clinical trials
Operationalizing Clinical Trials
Principal investigator role
Executive committee role
Steering committee role
Nurse coordinator clinical research associate role
Monitor role
Sponsor role
Randomization service
Central laboratory facility
EKG core laboratory
Angiographic core laboratory
MRI core laboratory
Genetics core laboratory
Biomarker core laboratory
Identification of sites
Recruitment of study participants
Schedule of events
Concomitant medications
Clinical event committee or event adjudication committee
Adverse events, serious adverse events and serious unexpected events
Data safety monitoring board (DSMB)
Study drug discontinuation, withdrawal of consent, incomplete follow up and lost to follow up patients
Protocol adherence
Storage and handling of investigational product
Data management and designing an electronic data capture form
Source documents
Study completion and close out
Protocol amendments
Publication committee
Statistical Analysis of Clinical Trials
Cleaning a dataset
Summary statistics
Intent to treat versus modified intent to treat versus as treated
Student's t tests and analysis of variance
Chi square analysis and Fisher's exact test
Handling missing data
Subgroup and interaction analyses
Net clinical benefit analyses
Cost effectiveness analyses
Quality adjusted life year analyses
Interim analyses and futility analyses
Reporting results and how to write a manuscript
Positive publication bias